Structure Therapeutics Inc.
GPCR
$21.76
$3.2317.43%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 49.41M | 46.79M | 42.18M | 37.49M | 32.67M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 158.23M | 142.16M | 122.47M | 115.14M | 102.78M |
| Operating Income | -158.23M | -142.16M | -122.47M | -115.14M | -102.78M |
| Income Before Tax | -122.22M | -110.69M | -100.26M | -97.44M | -89.38M |
| Income Tax Expenses | 310.00K | -138.00K | 175.00K | 240.00K | 236.00K |
| Earnings from Continuing Operations | -122.53 | -110.55 | -100.44 | -97.68 | -89.62 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -122.53M | -110.55M | -100.44M | -97.68M | -89.62M |
| EBIT | -158.23M | -142.16M | -122.47M | -115.14M | -102.78M |
| EBITDA | -157.23M | -141.34M | -121.84M | -114.67M | -102.46M |
| EPS Basic | -6.95 | -6.63 | -6.71 | -6.96 | -7.54 |
| Normalized Basic EPS | -1.31 | -1.33 | -1.35 | -1.40 | -1.52 |
| EPS Diluted | -6.95 | -6.63 | -6.71 | -6.96 | -7.54 |
| Normalized Diluted EPS | -1.31 | -1.33 | -1.35 | -1.40 | -1.52 |
| Average Basic Shares Outstanding | 210.50M | 199.51M | 180.62M | 169.46M | 146.77M |
| Average Diluted Shares Outstanding | 70.17M | 66.50M | 60.21M | 56.49M | 48.92M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |